Quarterly Cashflow and Activity Report

Apr 7th, 2020

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 March 2020.

Starpharma’s cash balance as at 31 March 2020 was $36.1 million, an increase of $0.2 million compared to the previous quarter’s cash balance. Net operating cash outflows for the quarter were $0.9 million, or $6.0 million for the nine months to 31 March 2020. Starpharma’s strong cash reserves and clean balance sheet places the Company in a strong position to continue to progress its commercial and R&D activities in the current uncertain global environment of the COVID-19 pandemic.

Okamoto licenses VivaGel® antiviral condom in Asian countries

Mar 4th, 2020

Starpharma today announced that following the successful launch of the VivaGel^® antiviral condom by Okamoto Industries, Inc. (TYO: 5122:JP; Okamoto) in Japan, Okamoto has sought an expansion to its licence territory for the VivaGel^® condom. As a result, Starpharma has granted Okamoto marketing rights to a further 11 countries in Asia which include South Korea, Indonesia, Malaysia, Thailand, Singapore and the non-government China market.

Starpharma appoints David McIntyre and Appendix 3X

Mar 2nd, 2020

Starpharma today announced that Mr David McIntyre has commenced as an independent non-executive director of Starpharma, effective 1 March. Mr McIntyre’s appointment follows a comprehensive Board renewal and search process. As advised at the Company’s last AGM, Mr Richard Hazleton will be retiring at the 2020 AGM in November, having served 13 years on the Company’s Board. The timing of Mr McIntyre’s appointment enables a smooth transition and handover between directors.

Interim Report and Half-Year Financial Results

Feb 24th, 2020

Starpharma today released its interim report and financial results for the half-year ended 31 December 2019.

Starpharma’s VivaGel® BV regulatory approvals continue in Asia

Sep 3rd, 2019

Read the full news coverage here.

Update on Starpharma’s latest positive interim DEP® trial results, VivaGel® and upcoming milestones

Aug 30th, 2019

To listen to the full interview, click here.

Starpharma sees positive results in ovarian cancer treatment

Aug 29th, 2019

To watch the full news video, click here.

Promising efficacy signals for Starpharma’s DEP® trials

Aug 28th, 2019

To read the full article, click here.

Shareholder Update January 2020

Jan 30th, 2020

In this issue: 

>> VivaGel^® BV launched in the UK

>> AstraZeneca first DEP^® product enters the clinic; triggers US$3M milestone

>> DEP^® cabazitaxel trial moves into phase 2 on positive results

>> Fleurstat BVgel marketing campaign; New Zealand launch planned

>> Dual strategy to achieve approval of the NDA in the US

>> Okamoto joins forces with Japanese government for STI prevention campaign

>> VivaGel^® condom receives regulatory approval in Europe

>> DEP^® docetaxel & DEP^® cabazitaxel clinical trial case studies

>> DEP^® irinotecan phase 1/2 trial

>> New candidate - DEP^® gemcitabine

>> GMP DEP^® facility licence

>> DEP^® combinations add further value

>> Outlook, recent news & events

Shareholder Update July 2019

Jul 1st, 2019

In this issue: 

>> VivaGel^® BV launched in Europe & Australia; US regulatory progress

>> VivaGel condom launched in Japan by Okamoto

>> DEP^® docetaxel & DEP^® cabazitaxel clinical trial update; DEP^® irinotecan trial start & new data

>> Starpharma signs second commercial oncology agreement with AstraZeneca

>> AstraZeneca highlights AZD0466 at 2019 ASCO meeting & upcoming US FDA IND 

>> Patent published for AstraZeneca Bcl2/xL DEP conjugates

>> DEP^® radiotherapeutics

>> Outlook, recent news & events